Researchers suggested that these findings support using minimal residual disease as a major stratification variable in all clinical trials to be conducted in patients with triple negative breast cancer.
These study results suggested that a longer time to surgery does not lower overall survival for women with early-stage breast cancer who had to delay operations due to the COVID-19 pandemic.
The American Society of Hematology released guidelines that “take providers through the conversations they have with newly diagnosed patients, almost in real-time.”
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
The study is evaluating itolizumab in patients with severe acute graft-versus-host disease as a first-line treatment concomitant with standard of care.